

1


2Supplementary figure 1. Co-immunoprecipitation of CD147 and ANXA2 in OVCAR3 and ES-2 cells.

(A,B) Cell lysates from OVCAR3 and ES-2 cell lines were subjected to immunoprecipitation with anti-ANXA2 antibody (A) and anti-CD147 antibody (B) and then immunoblotted with anti-CD147 antibody (A) and anti-ANXA2 antibody (B), “IgG”

representing the negative control. “Input” was total cell lysate of OVCAR3 and ES-2. ANXA2: annexin II

6

The correlation between CD147 and HE4 protein in ovarian cancer




7

8 Supplementary figure 2. The correlation between the expression of CD147 and HE4 protein in ovarian cancer

9

10
11
12



13

14 **Supplementary figure 3. Interaction effects between CD147 and ANXA2 in OVCAR3 and ES-2 cells**

15 (A) The expression of ANXA2 was not affected by the downregulation of CD147 in OVCAR3 and ES-2 cells. (B)


16 Expression of CD147 was not affected after downregulation of ANXA2 in OVCAR3 and ES-2 cells.

17

18

19

20



21 **Supplementary figure 4. Secondary antibody alone served as a negative control in ovarian cancer**
22 **cells by immunocytochemistry.**

23

24

25

26

27

Supplementary Table 1 Kaplan-Meier analysis of the prognosis of ovarian cancer

Variable	Characteristics	(Log-rank) <i>p</i> -value
Age at diagnosis	<59y vs ≥59y	0.079
FIGO stage	I-II vs III-IV	0.001
Differentiation grade	Well vs poor	0.154
Lymphnode metastasis	No vs Yes	0.001
CD147	Low vs high	0.018
HE4	Low vs high	0.005

28

29